NGS Adoption in Action: Enabling Genomic Centers of Excellence
Accelerate Bioinformatics at Scale with Seven Bridges + Nextflow
Insourcing and sustaining next-generation sequencing (NGS) testing services still presents both strategic opportunities and operational challenges for many laboratories. In this session, a leading acute health care hospital laboratory will share its journey in establishing in-house NGS testing, from assay selection and validation to navigating reimbursement and optimizing clinical workflows under staffing and resource constraints.
Attendees will gain insights into how strategic collaboration and expert support enabled a successful implementation, streamlining validation processes, improving reimbursement readiness, and accelerating case review through a purpose-built clinical genomics platform. This session will highlight practical strategies and lessons learned that can help other laboratories enhance operational efficiency, manage cost pressures, and deliver competitive, high-quality genomic insights for hematologic cancer care.
Speakers
Dr. Anna Dobretsova
Manager of the Molecular Diagnostics Department at Northside Hospital – Atlanta, Georgia.
The lab’s services include next-generation sequencing (NGS) panels for myeloid cancers, myeloproliferative neoplasm (MPN) screening, and targeted mutational analysis for FLT3 and NPM-1. The lab also performs post-transplant chimerism analysis, quantitative PCR for BCR-ABL monitoring, and various viral loads and testing for coagulation factors.
Before joining Northside Hospital, Dobretsova served as a research assistant professor and a postdoctoral fellow in the Department of Physiology & Biophysics at the University of Arkansas for Medical Sciences. She earned her doctorate in molecular neuroscience from the same institution in 2000.